摘要
目的 探讨体重指数预测乳腺癌新辅助化疗的疗效和预后的价值.方法 收集广东省妇幼保健院2007年1月-2013年12月收治的99例接受新辅助化疗ⅡB～ⅢC期的乳腺癌患者的临床资料,分析体重指数和乳腺癌新辅助化疗的疗效和预后的关系.结果 所有患者临床完全缓解率为12.1％（12/99）,部分缓解率为68.7％ （68/99）,稳定或进展率为19.2％（19/99）,总体有效率为80.8％（80/99）,病理完全缓解率为9.1％（9/99）.体重指数与新辅助化疗有效率相关（P=0.039）,与病理完全缓解率无关（P=0.454）.单因素分析和多因素分析发现,体重指数与无病生存率和总生存率不相关（P＞0.05）.结论 体重指数与乳腺癌新辅助化疗临床有效率相关,超重或肥胖可能预测乳腺癌新辅助化疗疗效不佳.体重指数是否影响乳腺癌新辅助化疗患者的预后尚不明确,需进一步研究.
Objective Resarech on the value of body mass index （BMI） predicting efficacy of neoadjuvant chemotherapy and prognostic in breast cancer.Methods Clinical data of 99 patients who received neoadjuvant chemotherapy Ⅱ B-Ⅲ C stage breast cancer patients was collected between January 2007 and December 2013 in Women and Children Hospital of Guangdong Province.Anaslysing the relation of BMI and efficacy of neoadjuvant chemotherapy and prognosis.Results In the study, Clinaical complete ressiom was 12.1％ （12/99）, partal ressiom was 68.7％ （68/99）, stable disease or disease progression was 19.2％ （19/99）, respone rate was 80.8％ （80/99）, pathlogic complete ression was 9.1％ （9/99）.BMI was significantly associated with response rate（P =0.039）, but not with pathlogic complete ression （P =0.454）.Univariate and multivariate analysis showed that BMI was not significantly associated with disease free survival and overall survival（P ＞ 0.05）.Conclusions BMI was significantly associated with response rate, overweight or obese patients would prodict poorly efficacy of neoadjuvant chemotherapy.The relationg of BMI and prognosis of breast cancer who accepted neoadjuvant chemotherapy is not clear, for further study.
出处
《国际外科学杂志》
2015年第9期619-623,共5页
International Journal of Surgery
基金
广东省医学科研基金（No.B2014023）
关键词
体重指数
乳腺肿瘤
化疗
Body mass index
Breast neoplasms
Chemotherapy
